Search
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational2019 under the brand name Padcev<sup>TM</sup>. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Imatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalThe discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4. … [L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized
Sofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalThis is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy.
Bethanechol
go.drugbank.com/drugs/DB01019ApprovedAn advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539] … [A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous
Metaraminol
go.drugbank.com/drugs/DB00610ApprovedIt has been used primarily as a vasoconstrictor in the treatment of hypotension. … An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedGrowth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. … While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection
Venlafaxine
go.drugbank.com/drugs/DB00285ApprovedInvestigational[L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. … for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: VENLAVITAE® 75 MG CÁPSULAS DURAS DE LIBERACIÓN PROLONGADAIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.